茂化實華(000637.SZ):全資子公司湛江實華兩項目正式投產
格隆匯7月14日丨茂化實華(000637.SZ)公佈,公司全資子公司湛江實華化工有限公司14萬噸/年裂解碳九及裂解焦油綜合利用項目和30萬噸/年(27.5%計)過氧化氫項目原預計於2020年12月投產,但受新冠疫情影響,延遲了項目建設進度。2021年4月後,兩項目陸續進入前期調試聯合試車,進行試生產。
截至2021年7月12日,14萬噸/年裂解碳九及裂解焦油綜合利用項目之加氫單元及分離單元和30萬噸/年(27.5%計)過氧化氫項目正式投入生產,產品合格,並向市場銷售。14萬噸/年裂解碳九及裂解焦油綜合利用項目之樹脂單元將根據市場需求、原料供應以及效益測算情況安排投入生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.